Critical Care Alert – November 1, 2021
November 1, 2021
View Archives Issues
This special feature will focus on dexmedetomidine as a sedative for invasive mechanical ventilation in the ICU.
In a multicenter, randomized clinical trial of critically ill COVID-19 patients, intermediate-dose compared to standard-dose prophylactic anticoagulation did not result in significant differences in the rates of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days.